iGEM 2019 — Team Aalto-Helsinki

[![](https://2019.igem.org/wiki/images/8/8b/HQ_page_logo.jpg)](https://2019.igem.org)

# Team:Aalto-Helsinki/Notebook

![](https://static.igem.org/mediawiki/2019/3/3c/Igem_mobile_menu_logo.svg)

![](https://static.igem.org/mediawiki/2019/e/ee/2019_team_menu_icon.svg)

[![](https://placehold.it/350x150/ececec/cecece)](https://2019.igem.org/Team%3AAalto-Helsinki)
[HOME](https://2019.igem.org/Team%3AAalto-Helsinki)

TEAM

[Team Members](https://2019.igem.org/Team%3AAalto-Helsinki/Team)
[Collaborations](https://2019.igem.org/Team%3AAalto-Helsinki/Collaborations)

PROJECT

[Description](https://2019.igem.org/Team%3AAalto-Helsinki/Description)
[Design](https://2019.igem.org/Team%3AAalto-Helsinki/Design)
[Experiments](https://2019.igem.org/Team%3AAalto-Helsinki/Experiments)
[Notebook](https://2019.igem.org/Team%3AAalto-Helsinki/Notebook)
[Contribution](https://2019.igem.org/Team%3AAalto-Helsinki/Contribution)
[Results](https://2019.igem.org/Team%3AAalto-Helsinki/Results)
[Demonstrate](https://2019.igem.org/Team%3AAalto-Helsinki/Demonstrate)
[Improve](https://2019.igem.org/Team%3AAalto-Helsinki/Improve)
[Attributions](https://2019.igem.org/Team%3AAalto-Helsinki/Attributions)

PARTS

[Parts Overview](https://2019.igem.org/Team%3AAalto-Helsinki/Parts)
[Basic Parts](https://2019.igem.org/Team%3AAalto-Helsinki/Basic_Part)
[Composite Parts](https://2019.igem.org/Team%3AAalto-Helsinki/Composite_Part)
[Part Collection](https://2019.igem.org/Team%3AAalto-Helsinki/Part_Collection)

[SAFETY](https://2019.igem.org/Team%3AAalto-Helsinki/Safety)

HUMAN PRACTICES

[Human Practices](https://2019.igem.org/Team%3AAalto-Helsinki/Human_Practices)
[Education & Engagement](https://2019.igem.org/Team%3AAalto-Helsinki/Public_Engagement)

AWARDS

[Entrepreneurship](https://2019.igem.org/Team%3AAalto-Helsinki/Entrepreneurship)
[Hardware](https://2019.igem.org/Team%3AAalto-Helsinki/Hardware)
[Measurement](https://2019.igem.org/Team%3AAalto-Helsinki/Measurement)
[Model](https://2019.igem.org/Team%3AAalto-Helsinki/Model)
[Plant](https://2019.igem.org/Team%3AAalto-Helsinki/Plant)
[Software](https://2019.igem.org/Team%3AAalto-Helsinki/Software)

[JUDGING FORM ⇗](https://igem.org/2019_Judging_Form?team=Aalto-Helsinki)

Aalto-Helsinki

![](https://static.igem.org/mediawiki/2019/8/81/T--Aalto-Helsinki--vibxpresso_logo.png)

* [Home](https://2019.igem.org/Team%3AAalto-Helsinki)
* [Project](https://2019.igem.org/Team%3AAalto-Helsinki/Description)
  + [Description](https://2019.igem.org/Team%3AAalto-Helsinki/Description)
  + [Design](https://2019.igem.org/Team%3AAalto-Helsinki/Design)
  + Notebook
* [Lab](https://2019.igem.org/Team%3AAalto-Helsinki/Lab)
  + Wet Lab
    - [Safety](https://2019.igem.org/Team%3AAalto-Helsinki/Safety)
    - [Experiments](https://2019.igem.org/Team%3AAalto-Helsinki/Experiments)
    - [Results](https://2019.igem.org/Team%3AAalto-Helsinki/Demonstrate)
  + Dry Lab
    - [Model](https://2019.igem.org/Team%3AAalto-Helsinki/Model)
* [Parts](https://2019.igem.org/Team%3AAalto-Helsinki/Parts)
* [Human Practices](https://2019.igem.org/Team%3AAalto-Helsinki/Human_Practices/Overview)
  + [Education & Public Engagement](https://2019.igem.org/Team%3AAalto-Helsinki/Public_Engagement)
  + [Collaborations](https://2019.igem.org/Team%3AAalto-Helsinki/Collaborations)
  + [Integrated Human Practices](https://2019.igem.org/Team%3AAalto-Helsinki/Human_Practices)
    - [Entrepreneurship](https://2019.igem.org/Team%3AAalto-Helsinki/Entrepreneurship)
* [Team](https://2019.igem.org/Team%3AAalto-Helsinki/Team)
  + [Attributions](https://2019.igem.org/Team%3AAalto-Helsinki/Attributions)
  + [Sponsors](https://2019.igem.org/Team%3AAalto-Helsinki/Sponsors)
* [Awards](https://2019.igem.org/Team%3AAalto-Helsinki/Awards)
  + [Judging Form](https://igem.org/2019_Judging_Form?id=3016)

# Notebook

## Team

## Human Practices

## Lab

## January

28.1.2019 - 1.2.2019
 The previous team interviewed the possible candidates for this year’s iGEM project

## February

8.2.2019
 Team selection is made

24.2.2019
 Our very first meeting!

The 2018 team prepared us for the upcoming project

## March

3.3.2019
 Brainstorming and general planning of the project

8.3.2019
 We met Heli Viskari and Markus Linder; our advisors from Aalto University

14.3.2019
 We met Minna Poranen from HiLIFE (Helsinki Institute of Life Science) and she became our advisor from the University of Helsinki

30.3.2019
 We met with the other Finnish iGEM team from Turku and invited some iGEM alumni to join. We presented our initial project ideas and had dinner together!

## April

5.4.2019 - 28.4.2019
 Several meetings with the team, advisors and sponsors: We found out about Vibrio natriegens and its possible applications

6.4.2019
 We held our first fun day and played board games together

We raised money to make our project possible

We started collaborations with Aalto Design Factory

12.4.2019 - 14.4.2019
 Some of our team members attended the Biobrick tutorial weekend in Copenhagen

25.4.2019
 We attended the biotech theme week planning meeting since we will take part in it in September

## May

2.5.2019 - 26.5.2019
 We researched Vibrio natriegens more and decided on the method that we will use to enhance its protein production

11.5.2019
 We had an association meeting with the previous team and made agreements on organizational things

24.5.2019
 We had a relaxed get-together with previous Aalto-Helsinki iGEM alumni

We continued fundraising and raised money for the project

13.5.2019
 We had a team coaching session with Caleidocons Oy to make our teamwork smooth during this project

17.5.2019
 HiLIFE (Helsinki Institute of Life Science) kindly decided to support our project

17.5.2019 - 19.5.2019
 We attended the Nordic iGEM Conference in Copenhagen

24.5.2019
 Meeting with Heureka Science Park to plan the event that we will organize for kids in September

27.5.2019
 We visited Thermo Fisher Scientific Ltd, our long-term partner, and they kindly decided to support our project

28.5.2019
 Loimu ry, the Union of Professionals in Natural, Environmental and Forestry Sciences, kindly decided to support our project

Lab inventory, lab design, Lab order planning, Lab introduction and safety introduction

## June

3.6.2019
Beginning of full-time work!

17.6.2019
Collaboration planning with Lund and Linköping

5.6.2019
 Presentation coaching for our team organized by Aalto University School of Business

7.6.2019
 We attended Terkko Healthcare Accelerator’s showcase where we got to see different pitches from life science -startups

11.6.2019
Planning meeting with Heureka Science Park

12.6.2019
 Meeting with Kemianteollisuus ry and they kindly decided to support our project

13.6.2019
 Second biotech theme week planning meeting

13.6.2019
 Bio Business Angel and Investor event where we pitched our project

17.6.2019
 We presented iGEM and our project to French pharma/business students

19.6.2019
 We discussed about pharmaceutical industry with Lääketeollisuus ry

18.6.2019
 We conducted our first trials of Biobricks and everyone in our team got experience in the lab

Lab inventory, Experimental design, DNA strand designs & orders, competent cell preparation & testing, Digestion, ligation & transformation practices for the team, BioBrick tutorial for the team

## July

26.7.2019 - 27.7.2019
We attended the European iGEM Meetup in Paris

3.7.2019
 We interviewed children’s endocrinologist Päivi Miettinen at Helsinki University Hospital

24.7.2019
 We interviewed children’s endocrinologist Risto Lapatto at Helsinki University Hospital

We interviewed Martin Dueblin, the managing director of One One Eleven GmbH and professional in the life sciences industry, and gained insights into our integrated human practices

Competent cell preparation & testing, primer designing, Digestions, ligations & transformations, DNA extractions, Tat signal sequence testing, qPCR, cPCR

## August

15.8.2019

We attended an Aalto-Helsinki iGEM alumni get-together and had a leisurely evening in Helsinki

17.8.2019
 iGEM meetup with Team Aboa

6.8.2019
 We interviewed Tarja Kähkönen, Healthcare District Leader, and Anssi Linnankivi, Medical Leader at Roche, to discuss the current state of drug development

8.8.2019

 We took part in organizing a training for high school students for the International Biology Olympiad (IBO)

9.8.2019

Presentation coaching organized by Aalto University School of Business, which we continued to have almost weekly until the final conference in Boston

12.8.2019
 We interviewed Jari Vehmaanperä, Global R&D Leader at Roal, to discuss the manufacturing of proteins

13.8.2019
We interviewed a patient using insulin to gain insights from the patient’s perspective

14.8.2019
We interviewed Tero Saukkonen; Clinical, Medical Regulatory Director at Novo Nordisk in Finland to discuss the business model of a pharmaceutical company

17.8.2019
We had another relaxing meeting with the other Finnish iGEM -team from Turku

26.8.2019
We presented iGEM and our project to high school students in Mäkelänrinne sports high school

27.8.2019
We presented iGEM and our project to high school students in Viikin normaalilukio

DNA amplification, primer designing, construct building and testing

## September

20-21.9.2019

We attended an iGEM meetup in Leuven, Belgium

14.9.2019

 We organized an event for kids in Heureka Science park, which was a huge success

26.9.2019

We attended a biotech theme week pitching competition

27.9.2019

We attended a biogarage opening event at Aalto University and organized a workshop

27.9.2019
Our first podcast episode was released! The episode featured Merja Penttilä, the adjunct professor of biotechnology at Aalto University.

30.9.2019

 We sent the hypothetical business model of our project in collaboration with UNSW iGEM team

Constructs building and testing, chromosomal editing, induction experiments, qPCR

## October

21.10.2019
Wiki Freeze!

30.10.2019-4.11.2019
The Giant Jamboree in Boston

8.10.2019
Our second podcast episode was released! The episode featured Pauli Kallio, the adjunct professor of molecular plant biology at the University of Turku.

11.10.2019
Our third podcast episode was released! The episode featured Lauri Reuter, Ph.D in biotechnology.

17.10.2019
We presented iGEM and our project for the translational medicine students at the University of Helsinki

Chromosomal editing, induction experiments, fractioning, qPCR, protein concentration measurements

[PROJECT](https://2019.igem.org/Team%3AAalto-Helsinki/Description)

[LAB](https://2019.igem.org/Team%3AAalto-Helsinki/Lab)

[HUMAN
OUTREACH](https://2019.igem.org/Team%3AAalto-Helsinki/Human_Practices)

![](https://static.igem.org/mediawiki/2019/2/2d/T--Aalto-Helsinki--aaltobiz.png)

![](https://static.igem.org/mediawiki/2019/b/b4/T--Aalto-Helsinki--aaltochem.png)

![](https://static.igem.org/mediawiki/2019/3/37/T--Aalto-Helsinki--aaltoelec.png)

![](https://static.igem.org/mediawiki/2019/d/d6/T--Aalto-Helsinki--aaltoeng.png)

![](https://static.igem.org/mediawiki/2019/e/e3/T--Aalto-Helsinki--aaltosci.png)

![](https://static.igem.org/mediawiki/2019/4/48/T--Aalto-Helsinki--aaltodf.png)

![](https://static.igem.org/mediawiki/2019/0/0a/T--Aalto-Helsinki--helsinki.png)

![](https://static.igem.org/mediawiki/2019/f/ff/T--Aalto-Helsinki--hilife.png)

![](https://static.igem.org/mediawiki/2019/0/07/T--Aalto-Helsinki--kemianteollisuus.png)

![](https://static.igem.org/mediawiki/2019/a/aa/T--Aalto-Helsinki--loimu.png)

![](https://static.igem.org/mediawiki/2019/b/b0/T--Aalto-Helsinki--thermofisher.jpg)

Kemistintie 1, Espoo, Finland
team@aaltohelsinki.com


[![](https://2019.igem.org/wiki/images/8/8b/HQ_page_logo.jpg)](https://2019.igem.org)

# Team:Aalto-Helsinki/Experiments

![](https://static.igem.org/mediawiki/2019/3/3c/Igem_mobile_menu_logo.svg)

![](https://static.igem.org/mediawiki/2019/e/ee/2019_team_menu_icon.svg)

[![](https://placehold.it/350x150/ececec/cecece)](https://2019.igem.org/Team%3AAalto-Helsinki)
[HOME](https://2019.igem.org/Team%3AAalto-Helsinki)

TEAM

[Team Members](https://2019.igem.org/Team%3AAalto-Helsinki/Team)
[Collaborations](https://2019.igem.org/Team%3AAalto-Helsinki/Collaborations)

PROJECT

[Description](https://2019.igem.org/Team%3AAalto-Helsinki/Description)
[Design](https://2019.igem.org/Team%3AAalto-Helsinki/Design)
[Experiments](https://2019.igem.org/Team%3AAalto-Helsinki/Experiments)
[Notebook](https://2019.igem.org/Team%3AAalto-Helsinki/Notebook)
[Contribution](https://2019.igem.org/Team%3AAalto-Helsinki/Contribution)
[Results](https://2019.igem.org/Team%3AAalto-Helsinki/Results)
[Demonstrate](https://2019.igem.org/Team%3AAalto-Helsinki/Demonstrate)
[Improve](https://2019.igem.org/Team%3AAalto-Helsinki/Improve)
[Attributions](https://2019.igem.org/Team%3AAalto-Helsinki/Attributions)

PARTS

[Parts Overview](https://2019.igem.org/Team%3AAalto-Helsinki/Parts)
[Basic Parts](https://2019.igem.org/Team%3AAalto-Helsinki/Basic_Part)
[Composite Parts](https://2019.igem.org/Team%3AAalto-Helsinki/Composite_Part)
[Part Collection](https://2019.igem.org/Team%3AAalto-Helsinki/Part_Collection)

[SAFETY](https://2019.igem.org/Team%3AAalto-Helsinki/Safety)

HUMAN PRACTICES

[Human Practices](https://2019.igem.org/Team%3AAalto-Helsinki/Human_Practices)
[Education & Engagement](https://2019.igem.org/Team%3AAalto-Helsinki/Public_Engagement)

AWARDS

[Entrepreneurship](https://2019.igem.org/Team%3AAalto-Helsinki/Entrepreneurship)
[Hardware](https://2019.igem.org/Team%3AAalto-Helsinki/Hardware)
[Measurement](https://2019.igem.org/Team%3AAalto-Helsinki/Measurement)
[Model](https://2019.igem.org/Team%3AAalto-Helsinki/Model)
[Plant](https://2019.igem.org/Team%3AAalto-Helsinki/Plant)
[Software](https://2019.igem.org/Team%3AAalto-Helsinki/Software)

[JUDGING FORM ⇗](https://igem.org/2019_Judging_Form?team=Aalto-Helsinki)

Aalto-Helsinki

![](https://static.igem.org/mediawiki/2019/8/81/T--Aalto-Helsinki--vibxpresso_logo.png)

* [Home](https://2019.igem.org/Team%3AAalto-Helsinki)
* [Project](https://2019.igem.org/Team%3AAalto-Helsinki/Description)
  + [Description](https://2019.igem.org/Team%3AAalto-Helsinki/Description)
  + [Design](https://2019.igem.org/Team%3AAalto-Helsinki/Design)
  + [Notebook](https://2019.igem.org/Team%3AAalto-Helsinki/Notebook)
* [Lab](https://2019.igem.org/Team%3AAalto-Helsinki/Lab)
  + Wet Lab
    - [Safety](https://2019.igem.org/Team%3AAalto-Helsinki/Safety)
    - Experiments
    - [Results](https://2019.igem.org/Team%3AAalto-Helsinki/Demonstrate)
  + Dry Lab
    - [Model](https://2019.igem.org/Team%3AAalto-Helsinki/Model)
* [Parts](https://2019.igem.org/Team%3AAalto-Helsinki/Parts)
* [Human Practices](https://2019.igem.org/Team%3AAalto-Helsinki/Human_Practices/Overview)
  + [Education & Public Engagement](https://2019.igem.org/Team%3AAalto-Helsinki/Public_Engagement)
  + [Collaborations](https://2019.igem.org/Team%3AAalto-Helsinki/Collaborations)
  + [Integrated Human Practices](https://2019.igem.org/Team%3AAalto-Helsinki/Human_Practices)
    - [Entrepreneurship](https://2019.igem.org/Team%3AAalto-Helsinki/Entrepreneurship)
* [Team](https://2019.igem.org/Team%3AAalto-Helsinki/Team)
  + [Attributions](https://2019.igem.org/Team%3AAalto-Helsinki/Attributions)
  + [Sponsors](https://2019.igem.org/Team%3AAalto-Helsinki/Sponsors)
* [Awards](https://2019.igem.org/Team%3AAalto-Helsinki/Awards)
  + [Judging Form](https://igem.org/2019_Judging_Form?id=3016)

# EXPERIMENTS

To see all the protocols our team used, please check the [Protocols](https://static.igem.org/mediawiki/2019/e/e4/T--Aalto-Helsinki--protocols_AH_new.pdf) link. Also check out our [Lab Notebook](https://static.igem.org/mediawiki/2019/0/01/T--Aalto-Helsinki--lab_notebook_AaltoHelsinki.pdf).

## VIBRIO NATRIEGENS ATCC 14048 / DSM 759 AND VMAX STRAINS

We obtained our *V. natriegens* ATCC DSM 759 strain (WT) from DSMZ, but before work with it began, we established basic workflows, protocols (see [Protocols](https://static.igem.org/mediawiki/2019/e/e4/T--Aalto-Helsinki--protocols_AH_new.pdf)), growth mediums, and other materials by working with Synthetic Genomic’s Vmax strain. Vmax is a commercial Vibrio natriegens strain, with an extracellular nuclease knockout and IPTG inducible T7 RNA Polymerase addition (Synthetic Genomics, 2017). After this, we released the WT strain and started to work with it, while maintaining the Vmax strain in parallel in some of the experiments.

## DNA SEQUENCES

To search for putative signal sequences from *V. natriegens* DSM 759 strain, we performed a BLAST search based on the S/T-R-R-x-F-L-K consensus sequence usually found in leader peptides of Tat pathway targeted proteins (Lee *et al.*, 2006). The results were then analysed for signal peptides using Phobius (http://phobius.sbc.su.se), and the most promising signal sequence from trimethylamine N-oxide reductase (ssTorA), was chosen for experiments. A homologous version of *ssTorA* in *E. coli* is well known to function with the Tat pathway of the respective bacterium (Blaudeck *et al.*, 2001; Lee *et al.*, 2006; Alanen *et al.*, 2015).

Synthetic DNA fragments with *ssTorA* and other putative signal peptides attached to the YGFP and human growth hormone (hGH) were ordered from Twist DNA. All sequences ordered and received are listed below. Originally we designed the sequences with restriction enzyme cut sites that would enable us to clone them into pQE-30 vector. However, this was changed when plans improved, and we started using PCR to change the cut sites to suit our cloning needs for pC201 and pC201 backbones.

![](https://static.igem.org/mediawiki/2019/5/5f/T--Aalto-Helsinki--sstora_ygfp.png)
![](https://static.igem.org/mediawiki/2019/3/3a/T--Aalto-Helsinki--aminotrs_ygfp.png)
![](https://static.igem.org/mediawiki/2019/3/37/T--Aalto-Helsinki--sstora_hgh.png)
![](https://static.igem.org/mediawiki/2019/f/fb/T--Aalto-Helsinki--aminotrs_hgh.png)
![](https://static.igem.org/mediawiki/2019/a/a1/T--Aalto-Helsinki--copper_ygfp.png)
![](https://static.igem.org/mediawiki/2019/5/5f/T--Aalto-Helsinki--duf1_ygfp.png)
![](https://static.igem.org/mediawiki/2019/7/70/T--Aalto-Helsinki--tetra_ygfp.png)
![](https://static.igem.org/mediawiki/2019/a/a9/T--Aalto-Helsinki--duf2_ygfp.png)

## CLONING

Plasmids pC203 and pC201 were chosen for expression tests because of their availability but also characteristics: they harbored the p15A ori which was known to work in *V. natriegens* with quite low copy number, had suitable antibiotic resistance for selection, and included inducible, tightly controlled promoters. We believed that these features would allow us to experiment with different genes and expression levels in a not so known host organism.

The original pC203 we received from Christopher Jonkergouw contained a pluR insert without suitable restriction sites for removal. The pC203 backbone was PCR’d using a forward primer annealing to the MCS and a reverse primer containing a 5’ overhang with PstI and EcoRI restriction sites annealing before the pluR gene. Thus we had created a easy-to-use expression backbone for our gene constructs.

![](https://static.igem.org/mediawiki/2019/e/ea/T--Aalto-Helsinki--pc203_plasmid.jpg)
Image: Original PC203 plasmid that we used as a backbone for our own plasmid constructs (generated by Benchling).

The PCR for pC203 was performed with our designed primers PC20x\_dPluR/dProm fwd & PC203\_dPluR rev (anneal T= 62.3C) to remove the unnecessary CDS *PluR* , and confirmed with electrophoresis gel that we had successfully performed PCR (pC203 without PluR = 4880bp). We also designed and performed *PluR* removal for plasmid pC201. PCR was performed with Thermo Fisher Scientific’s Phusion polymerase.

![](https://static.igem.org/mediawiki/2019/1/1f/T--Aalto-Helsinki--primer_plur_removal.png)
![](https://static.igem.org/mediawiki/2019/7/71/T--Aalto-Helsinki--primer_tfox_ampli.png)

We successfully performed PCR and confirmed results with an electrophoresis gel showing a band at 690 bp for tfoX amplification

![](https://static.igem.org/mediawiki/2019/7/74/T--Aalto-Helsinki--pc203_tora_ygfp1.png)
Image: Insertion sequence confirmed pC203-ssTorA-YGFP plasmid chart (generated by Benchling).

![](https://static.igem.org/mediawiki/2019/3/3d/T--Aalto-Helsinki--pc203_tora_hgh1.png)

Image: Insertion sequence confirmed pC203-ssTorA-hGH plasmid chart (generated by Benchling).

![](https://static.igem.org/mediawiki/2019/b/b9/T--Aalto-Helsinki--pc203_tfox1.png)

Image: Insertion sequence confirmed pC203-tfoX plasmid chart (generated by Benchling).

After, we constructed an expression vector by digesting pC203-dPlur and Tfox with EcoRI & XbaI in separate tubes. We Dephosphorylated the digested pC203 with Thermo Fisher Scientific’s FastAP alkaline phosphatase. Then, we denatured the restriction enzymes and alkaline phosphatase. Ligation of the digested pieces was performed using Thermo Fisher Scientific’s T4 DNA Ligase, and the constructs were transformed into *V. natriegens* and plated on ampicillin containing V2+LB plate. Following plating, we screened for successful inserts using primers Tfox fwd & PC203\_insert\_conf rev (product = 690bp, anneal T =59,9C)

![](https://static.igem.org/mediawiki/2019/b/b9/T--Aalto-Helsinki--pc203_tfox1.png)

## TRANSFORMATIONS

Plasmids were transformed into either chemically competent or electrocompetent cells. We prepared both for *E. coli* DH5a cells, but only electrocompetent *V. natriegens* cells. Preparation and transformation protocols are listed in [Protocols](https://static.igem.org/mediawiki/2019/e/e4/T--Aalto-Helsinki--protocols_AH_new.pdf)

## INDUCTION EXPERIMENTS

**Induction of pC203-TorA-YGFPa**

Induction of pC203-TorA-YGFP was carried out in *Vibrio natriegens* (Vmax) and *Escherichia coli* (DH5a) in order to verify that the plasmid construct was working like expected and producing functional YGFP. Induced *E. coli* cells were used for microscopy after the experiment, and localisation of YGFP was observed in some of the cells.

**Preparing cultures for fluorescence experiments**

LB+amp (100 ug/ml) was inoculated with colonies of DH5a or *Vibrio natriegens* harboring pC201-TorA-YGFP and pC203-TorA-YGFP, and were grown overnight at 37 C with 230 rpm.

On the day of the experiment, overnight cultures were refreshed in LB + amp (100 ug/ml), and grown for 3h 230 rpm, 37 C.

**Experiment setup**

Cultures harboring pC201-TorA-YGFP were induced with L-arabinose.
Cultures harboring pC203-TorA-YGFP were induced with L-rhamnose.

The following range of both L-arabinose/L-rhamnose were used for induction with DH5a:

0,0 mM (only LB + amp)

0,001 mM

0,01 mM

0,05 mM

0,1 mM

0,5 mM

1 mM

5 mM

The following range of both L-arabinose/L-rhamnose were used for induction with *V. natriegens*:

0,0 mM (only LB + amp)

0,5 mM

2,5 mM

5 mM

10 mM

0,5 mM

1 mM

25 mM

For the experiments, 90 ul of LB+amp+inducer and 90 ul of cells were used, with a total volume of 180 ul/well. 90 ul of LB + amp (100 ug/ml) + inducer was first pipetted in each well. After this, 90 ul of each refreshed culture was added.
Measurement was carried out with Synergy H1 microplate reader (Biotek). Excitation read was set to 500 nm and emission to 530 nm. OD600 was measured from each well. Optics were read from the bottom of each well. Temperature was set at 37 C (+preheat) and the plate was under continuous shaking (230 rpm). Fluorescence and absorbance readings were measured every 10 min over 10 h. Mean fluorescence and OD600 values were calculated from three replicates for DH5a and DH5a+BBa\_J04450. Gen5 2.09 software was used for programming the experiment.

## qPCR FOR PLASMID COPY NUMBER QUANTIFICATION

Quantitative PCR (qPCR) was carried out to determine copy numbers of plasmids/cell in *Vibrio natriegens* according to a method described by Lee *et al.* (2006). Absolute quantification method was used. Briefly, the method involves isolating total DNA from the bacterium carrying the plasmid of interest. With two sets of primers, total DNA (genomic and plasmid) from the same sample was used as a template for qPCR. Amplification was targeted at the *bla* gene (encoding for beta-lactamase) and a housekeeping gene from the chromosome. Here we targeted the housekeeping gene *dxs*, encoding for 1-deoxy-D-xylulose-5-phosphate synthase, which was also used by Lee *et al.* (2006). The gene is typically present as one copy in the genome, and thus the amount of *dxs* gene copies in the sample is equal to the amount of cells. In *Vibrio, dxs* is present in only one of the two chromosomes, and the same principle can be applied. By dividing the number of plasmid copies by the number of copies of the *dxs* gene, plasmid copy number/cell (or per gDNA) was calculated.

**Plasmids**

Quantification was carried out for empty plasmid backbones of pUC18, pQE30 and pC203 plasmids, with pMB1, ColE1 and p15A origins of replication respectively. pC203 plasmid was used as an expression vector in our experiments. The copy number retrieved from the experiment was utilized in modeling.

**Preparation of the templates**

Plasmids were transformed into *Vibrio natriegens* (Vmax) with electroporation as described under “protocols”. Glyserol stocks were prepared from colonies grown from the transformation plate according to Vmax protocol and stored at - 80 C.
([https://www.biocat.com/bc/pdf/Vmax\_Express\_40026\_100517-Rev1.6.pdf). To isolate total DNA templates, cells were regrown on LB+amp (25 ug/ml) plates, and then individual colonies were used for starter cultures of each strain (*Vibrio natriegens* + pUC18, pQE30 or pC203). Starter cultures were prepared in 5 ml of LB+amp (25 ug/ml) medium, and grown at + 37 C, 220 rpm overnight. Next morning, about 300 ul of each starter culture was used to inoculate 5 ml of fresh LB+amp medium (25 ug/ml). Each strain was grown in triplicates. Total DNA was harvested at OD600 = 0.5 (exponential growth phase) for pUC18 and pQE30 harboring strains as suggested in the protocol by Lee *et al.* (2006). *Vibrio natriegens* harboring pC203 was isolated at OD600 = 1, as was done by Tschirhart *et al.* (2019). Total DNA was extracted with innuPREP Bacteria DNA Kit (Analytik Jena) according to protocol. DNA concentrations were in the range of 1635-2893,6 ng/ul, and were diluted 1:100 and stored at -20 C. 1:100 diluted samples were used as templates.](https://www.biocat.com/bc/pdf/Vmax_Express_40026_100517-Rev1.6.pdf)

**Preparation of standards**

As a standard, a dilution series of TOPO TA vector (Invitrogen) containing dxs gene cloned from *Vibrio natriegens* genome was used. Plasmid copy numbers were in the range of 6,057x10^9 - 6,057x10^3 copies/ul. Preparation of standards is presented under [Protocols](https://static.igem.org/mediawiki/2019/e/e4/T--Aalto-Helsinki--protocols_AH_new.pdf). Successful cloning of *dxs* into TOPO TA vector was verified by PCR and sequencing using the same set of primers. TOPO TA vector also contains the *bla* encoding gene, which was used as a target for amplification from pUC18, pQE30 and pC203 plasmids. The same standard was used as a template for quantifying both dxs and bla.

**qPCR assay**

qPCR was carried of with SensiFAST™ SYBR® No-ROX Kit (Bioline) according to protocol in 20 ul reactions. Total DNA templates were examined as biological triplicates and two technical replicates. Standards were examined in three technical replicates of each copy number (6,057x10^9 - 6,057x10^3copies/ul). No template controls were included. *Bla* and *dxs* targeting primers were used in separate wells, and therefore two master mixes were prepared (containing either *bla* or *dxs* targeting primers). Standards and templates were amplified using both sets of primers. The experiment was done using white 96-well Multiplate PCR Plates (Bio-Rad) and CFC Connect Real-Time System (Bio-Rad) machine.

Bla primers (from article by Lee et al., 2006)

```
                            bla_E.coli_F: 5’-CTA CGA TAC GGG AGG GCT TA-3’
```

```
                            bla_E.coli_R: 5’-ATA AAT CTG GAG CCG GTG AG-3’
```

qPCR program:1. 95 C, 3:00 min (1 cycle)
2. 95 C, 0:10 s
3. 60 C, 0:35 s
4. 72 C, 0:30 s (+ plate read) GOTO 2, repeat 39 x
5. Melt curve from 65 to 95 C, increment 0.5 C, for 0:05s (+plate read)
6. End

Cq values, melt curves and amplification curves were retrieved from the accompanied program. Melting curves were examined to check specificity of primers. Standard curves were plotted for *dxs* and *bla* from Cq values and known copy numbers of each gene. Unknown copy numbers of *bla* and *dxs* from total DNA templates were calculated from the equation retrieved from standard curves. Plasmid copy numbers were calculated by dividing the number of *bla* copies/ul with the number of *dxs* copies/ul. Standard curves for *dxs* and *bla* are presented below.

## CHROMOSONAL EDITING

To obtain our desired VibXPresso strain, we wanted to introduce chromosomal modifications into *Vibrio natriegens*. We planned to achieve this via homologous recombination, which in bacteria is a major DNA repair process. It also enables genetic diversity in bacteria. For this, we constructed a pC203-tfoX plasmid where we introduced *tfoX* gene. *tfoX* is a regulator of natural competence in *V. natriegens* (Dalia et al., 2017). This increases the efficiency of homologous recombination, making the editing easier.

After the construction of pC203-tfoX, we purified the plasmid and continued with chromosomal modifications. Our planned modifications included dns and tat deletions for *V. natriegens*. The *dns* deletion would increase the transformation efficiency of our strain and a tat deletion strain would be created to act as a control for our translocation studies.

For the planned dns deletion, we performed PCR to amplify the upstream region for homologous recombination vector using our designed primers Dns 2.6k upstream fwd & Dns OE cfwd-rev (anneal T= 62.7C), and the downstream region for homologous recombination vector using primers Dns 2.5k downstream rev & Dns OE crev-fwd (anneal T= 62.0C).

For the planned tat deletion, we also performed PCR to amplify the upstream region for homologous recombination vector using our designed primers TatO 2.54k upstream fwd & TatO OE cfwd-rev (anneal = 61.3), and the downstream region for homologous recombination vector using primers TatO 2.5k downstream rev & TatO OE crev-fwd (anneal T= 61.4C).

Due to time constraints, we decided to continue only with the dns deletion into the next step. In the next step, we combine pieces of upstream and downstream regions by overlap extension PCR (OE-PCR) to form a complete vector (anneal T = 72C). Overlap extension PCR (OE-PCR) is a method to scarlessly join together PCR fragments by utilizing primers containing a 5’-end overlap. This makes the fragments act as primers for each other, combining them in PCR. Normal primer design rules should be followed when designing the 5’-overlaps.

![](https://static.igem.org/mediawiki/2019/c/c5/T--Aalto-Helsinki--oepcr01.png)
Overlap extension PCR to delete a DNA sequence from the strand.

Next, we performed PCR with our designed primers Dns 2.6k upstream fwd & Dns 2.5k downstream rev to amplify complete vector (anneal T= 62.3C). After, we run an electrophoresis gel of PCR products from and extracted the band at 5000bp. We then transformed the complete vector into (naturally competent, induced Tfox expression plasmid containing) V. natriegens and plated transformed cells on ampicillin + V2 + LB containing plate. Next, we picked colonies and attempted to verify deletion by PCR using primers Dns 3.1k upstream fwd & Dns 3k downstream rev (anneal T = 63). Finally, we analyzed the product in electrophoresis gel (deletion-positive = 6000bp). The confirmation process was still happening at the time of the wiki freeze, so we don’t have a gel image of the confirmation.

![](https://static.igem.org/mediawiki/2019/e/e4/T--Aalto-Helsinki--primer_dns_tat.png)
![](https://static.igem.org/mediawiki/2019/f/f0/T--Aalto-Helsinki--primer_dns_tat2.png)

## CELL FRACTIONING

To test the expression and translocation of ssTorA-hGH, we decided to perform a cell fractionation experiment that would allow us to determine the localisation of leader signal including hGH in *V. natriegens*, while hGH without the signal peptide would serve as a control. Fractionation divides the cells into periplasmic, cytoplasmic and insoluble (membrane) fractions, that can then be analysed separately.

After researching for various fractionation methods, we decided on PureFrac that had been developed and used in fractionation of *E. coli* cells without detectable contamination between the fractions (Malherbe *et al.*, 2019). PureFrac uses osmotic shock with MgCl2 for the extraction of periplasmic fraction, and sonication for cell disruption. Sonication was performed with QSonica’s Tip Sonicator. The fractionation was applied successfully to our cells with few modifications to the original protocol (see [Protocols](https://static.igem.org/mediawiki/2019/e/e4/T--Aalto-Helsinki--protocols_AH_new.pdf)).

## WESTERN BLOT

For the detection of His tagged hGH, we blotted the different fractions to a nitrocellulose membrane using BioRad Trans-Blot Turbo (see [Protocols](https://static.igem.org/mediawiki/2019/e/e4/T--Aalto-Helsinki--protocols_AH_new.pdf)). Chemiluminescent imaging was performed in BioRad ChemiDoc MP imaging system.

**References:**

Alanen, H. I., Walker, K. L., Lourdes Velez Suberbie, M., Matos, C. F., Bonisch, S., Freedman, R. B., . . . Robinson, C. (2015). Efficient export of human growth hormone, interferon alpha2b and antibody fragments to the periplasm by the Escherichia coli Tat pathway in the absence of prior disulfide bond formation. Biochim Biophys Acta, 1853(3), 756-763. doi:10.1016/j.bbamcr.2014.12.027

Blaudeck, N., Sprenger, G. A., Freudl, R., & Wiegert, T. (2001). Specificity of signal peptide recognition in tat-dependent bacterial protein translocation. Journal of bacteriology, 183(2), 604–610. doi:10.1128/JB.183.2.604-610.2001

Dalia, T. N., Hayes, C. A., Stolyar, S., Marx, C. J., McKinlay, J. B., & Dalia, A. B. (2017). Multiplex genome editing by natural transformation (MuGENT) for synthetic biology in Vibrio natriegens. ACS synthetic biology, 6(9), 1650-1655.

Jong, W. S., Vikstrom, D., Houben, D., van den Berg van Saparoea, H. B., de Gier, J. W., & Luirink, J. (2017). Application of an E. coli signal sequence as a versatile inclusion body tag. Microb Cell Fact, 16(1), 50. doi:10.1186/s12934-017-0662-4

Lee, P. A., Tullman-Ercek, D., & Georgiou, G. (2006). The bacterial twin-arginine translocation pathway. Annual review of microbiology, 60, 373–395. doi:10.1146/annurev.micro.60.080805.142212

Synthetic Genomics, Inc. (2017). VmaxTM Express Electrocompetent Cells User Guide. La Jolla, CA: Synthetic Genomics.

Malherbe, G., Humphreys, D. P., & Davé, E. (2019). A robust fractionation method for protein subcellular localization studies in Escherichia coli. BioTechniques, 66(4), 171-178. doi:10.2144/btn-2018-0135

![](https://static.igem.org/mediawiki/2019/2/2d/T--Aalto-Helsinki--aaltobiz.png)

![](https://static.igem.org/mediawiki/2019/b/b4/T--Aalto-Helsinki--aaltochem.png)

![](https://static.igem.org/mediawiki/2019/3/37/T--Aalto-Helsinki--aaltoelec.png)

![](https://static.igem.org/mediawiki/2019/d/d6/T--Aalto-Helsinki--aaltoeng.png)

![](https://static.igem.org/mediawiki/2019/e/e3/T--Aalto-Helsinki--aaltosci.png)

![](https://static.igem.org/mediawiki/2019/4/48/T--Aalto-Helsinki--aaltodf.png)

![](https://static.igem.org/mediawiki/2019/0/0a/T--Aalto-Helsinki--helsinki.png)

![](https://static.igem.org/mediawiki/2019/f/ff/T--Aalto-Helsinki--hilife.png)

![](https://static.igem.org/mediawiki/2019/0/07/T--Aalto-Helsinki--kemianteollisuus.png)

![](https://static.igem.org/mediawiki/2019/a/aa/T--Aalto-Helsinki--loimu.png)

![](https://static.igem.org/mediawiki/2019/b/b0/T--Aalto-Helsinki--thermofisher.jpg)

Kemistintie 1, Espoo, Finland
team@aaltohelsinki.com

[![](https://2019.igem.org/wiki/images/8/8b/HQ_page_logo.jpg)](https://2019.igem.org)

# Team:Aalto-Helsinki/Results

![](https://static.igem.org/mediawiki/2019/3/3c/Igem_mobile_menu_logo.svg)

![](https://static.igem.org/mediawiki/2019/e/ee/2019_team_menu_icon.svg)

[![](https://placehold.it/350x150/ececec/cecece)](https://2019.igem.org/Team%3AAalto-Helsinki)
[HOME](https://2019.igem.org/Team%3AAalto-Helsinki)

TEAM

[Team Members](https://2019.igem.org/Team%3AAalto-Helsinki/Team)
[Collaborations](https://2019.igem.org/Team%3AAalto-Helsinki/Collaborations)

PROJECT

[Description](https://2019.igem.org/Team%3AAalto-Helsinki/Description)
[Design](https://2019.igem.org/Team%3AAalto-Helsinki/Design)
[Experiments](https://2019.igem.org/Team%3AAalto-Helsinki/Experiments)
[Notebook](https://2019.igem.org/Team%3AAalto-Helsinki/Notebook)
[Contribution](https://2019.igem.org/Team%3AAalto-Helsinki/Contribution)
[Results](https://2019.igem.org/Team%3AAalto-Helsinki/Results)
[Demonstrate](https://2019.igem.org/Team%3AAalto-Helsinki/Demonstrate)
[Improve](https://2019.igem.org/Team%3AAalto-Helsinki/Improve)
[Attributions](https://2019.igem.org/Team%3AAalto-Helsinki/Attributions)

PARTS

[Parts Overview](https://2019.igem.org/Team%3AAalto-Helsinki/Parts)
[Basic Parts](https://2019.igem.org/Team%3AAalto-Helsinki/Basic_Part)
[Composite Parts](https://2019.igem.org/Team%3AAalto-Helsinki/Composite_Part)
[Part Collection](https://2019.igem.org/Team%3AAalto-Helsinki/Part_Collection)

[SAFETY](https://2019.igem.org/Team%3AAalto-Helsinki/Safety)

HUMAN PRACTICES

[Human Practices](https://2019.igem.org/Team%3AAalto-Helsinki/Human_Practices)
[Education & Engagement](https://2019.igem.org/Team%3AAalto-Helsinki/Public_Engagement)

AWARDS

[Entrepreneurship](https://2019.igem.org/Team%3AAalto-Helsinki/Entrepreneurship)
[Hardware](https://2019.igem.org/Team%3AAalto-Helsinki/Hardware)
[Measurement](https://2019.igem.org/Team%3AAalto-Helsinki/Measurement)
[Model](https://2019.igem.org/Team%3AAalto-Helsinki/Model)
[Plant](https://2019.igem.org/Team%3AAalto-Helsinki/Plant)
[Software](https://2019.igem.org/Team%3AAalto-Helsinki/Software)

[JUDGING FORM ⇗](https://igem.org/2019_Judging_Form?team=Aalto-Helsinki)

# Results

Here you can describe the results of your project and your future plans.

### What should this page contain?

* Clearly and objectively describe the results of your work.
* Future plans for the project.
* Considerations for replicating the experiments.

### Describe what your results mean

* Interpretation of the results obtained during your project. Don't just show a plot/figure/graph/other, tell us what you think the data means. This is an important part of your project that the judges will look for.
* Show data, but remember **all measurement and characterization data must also be on the part's Main Page on the Registry.** Otherwise these data will not be in consideration for any medals or part awards!
* Consider including an analysis summary section to discuss what your results mean. Judges like to read what you think your data means, beyond all the data you have acquired during your project.

### Project Achievements

You can also include a list of bullet points (and links) of the successes and failures you have had over your summer. It is a quick reference page for the judges to see what you achieved during your summer.

* A list of linked bullet points of the successful results during your project
* A list of linked bullet points of the unsuccessful results during your project. This is about being scientifically honest. If you worked on an area for a long time with no success, tell us so we know where you put your effort.

### Inspiration

See how other teams presented their results.

* [2014 TU Darmstadt](https://2014.igem.org/Team%3ATU_Darmstadt/Results/Pathway)
* [2014 Imperial](https://2014.igem.org/Team%3AImperial/Results)
* [2014 Paris Bettencourt](https://2014.igem.org/Team%3AParis_Bettencourt/Results)